Figure 1
Figure 2
Figure 3
The value of NLR, PLR and ESR in the two subsets of Group A (n=31) and Group B (n=71)
| NLR | PLR | ESR (mm/h) | |
|---|---|---|---|
| Subset As (survivors, n=11) | 2,36 (0,87–8.36) | 138,82 (21,61–416,66) | 15 (6–110) |
| Subset Ad (deceased, n=20) | 2,77 (1,25–12,94) | 132,57 (41,11–371,17) | 62 (11–135) |
| Subset Bs (survivors, n=8) | 1,40 (1,32–1,73) | 112,89 (91,14–140,54) | 31 (9–90) |
| Subset Bd (deceased, n=63) | 3,59 (0,70–26,60) | 183,50 (3,38–651,25) | 44 (3–120) |
Characteristic of the patients with resectable (Group A) and nonresectable (Group B) lung cancer
| 102 patients | Age (years) | History of smoking (No, %) | PA (No) | Ne (/mm3) | Ly (/mm3) | PI (/mm3) | NLR | PLR | ESR (mm/h) |
|---|---|---|---|---|---|---|---|---|---|
| Group A (resectable stages) 31 (23 men) | 65 (51–83) | 23 74,2% | 40 (3–100) | 6380 (2600-22.000) | 2000 (1020-13.600) | 294.000 (111.000–709.000) | 2,74 (0,87–12,94) | 133,95 (21,61–416,66) | 35 (6–135) |
| Group B (nonresectable stages) 71 (63 men) | 67 (37–88) | 60 84,5% | 40 (4–90) | 6450 (1800–27.892) | 1800 (500–15.700) | 327.000 (23.000–661.000) | 3,51 (0,76–25,60) | 170,37 (3.38–651,25) | 40 (3–120) |